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Summary
Background How much the successful implementation of the most eﬀ ective (ie, best-practice) interventions could 
reduce socioeconomic inequalities of coronary heart disease mortality is not known. We assessed this issue in an 
occupational cohort study comparing low with high socioeconomic groups.  
Methods We undertook a prospective cohort study on 17 186 male civil servants aged 40–69 years between 1967 and 1970 
in the UK (the Whitehall study). Socioeconomic position was based on employment grade. We compared the potential 
reduction in excess coronary heart disease mortality in men of low with those of high socioeconomic position with 
either best-practice interventions (reduction of systolic blood pressure by 10 mm Hg, of total cholesterol by 2 mmol/L, 
and of blood glucose by 1 mmol/L in pre-diabetic people; halving the prevalence of non-insulin-dependent diabetes; 
and complete cessation of cigarette smoking) or primordial prevention. 
Findings 15-year absolute risk of death due to coronary heart disease per 100 men, standardised to age 55 years, was 
11·0 for men in the low employment grade group and 7·5 for those in the high grade group. Population-wide 
best-practice interventions would reduce coronary heart disease mortality by 57%, and the diﬀ erence in mortality 
between socioeconomic groups by 69%. For primordial prevention, the corresponding reductions would be 73% 
and 86%, respectively.
Interpretation Our results suggest that current best-practice interventions to reduce classic coronary risk factors, if 
successfully implemented in both high and low socioeconomic groups, could eliminate most of the socioeconomic 
diﬀ erences in coronary heart disease mortality. Modest further beneﬁ ts would result if the classic coronary risk factors 
could be reduced to primordial levels for the whole population.
Funding Department of Health and Social Security (UK), Tobacco Research Council (UK), British Heart Foundation 
(UK), Medical Research Council (UK), European Science Foundation (EU), Wellcome Trust (UK), and Academy of 
Finland (Finland). 
Introduction
The most eﬀ ective ways to reduce socioeconomic 
inequalities in coronary heart disease—a leading cause 
of death—are not known.1–3 Studies have assessed the 
contribution of various risk factors to socioeconomic 
inequalities by comparing the relative risk of coronary 
heart disease between high and low socioeconomic 
groups before and after adjustment for these risk 
factors.4–7 The drawback of this method is that it does not 
take into account the extent to which reduction in each 
risk factor is feasible because it simply approximates 
what would happen after standardisation to the risk-factor 
distribution in the total study population.
Classic, well-established risk factors of coronary heart 
disease are high blood pressure, high cholesterol, 
diabetes mellitus, and cigarette smoking.8–10 The most 
successful (ie, best-practice) pharmacological and lifestyle 
interventions to date have reduced systolic blood pressure 
by about 10 mm Hg,11 total cholesterol by 2 mmol/L,12 
blood glucose in pre-diabetic people by 1 mmol/L, and 
have halved the prevalence of non-insulin-dependent 
diabetes mellitus (non-IDDM) in adults.13 With existing 
databases, the extent to which successful implementation 
of these best-practice inter ventions could reduce 
socioeconomic inequalities in coronary heart disease at 
the population level can be estimated.9,14 
Here, we assessed—both in absolute and relative 
terms—what would happen to socioeconomic in equalities 
in coronary heart disease if these best-practice risk 
reductions applied to both high and low socio economic 
groups. We also measured potential risk reduction if all 
smokers quit. New aggressive anti-smoking policies and 
reduction in smoking from 82% to 26% among men in 
the UK over the past 60 years gave at least an approximation 
to this scenario that is more plausible than envisaged.15 
We also assessed the eﬀ ects on socioeconomic 
inequalities of a primordial prevention strategy based on 
risk-factor levels below those currently observed in 
developed societies. The increase in blood pressure with 
age is not physiologically inevitable,16 and diabetes 
prevalence is low in the absence of diets and obesity rates 
that are typical of developed countries.17,18 Apart from a 
small proportion of people with a strong genetic 
predisposition to hyper chol esterolaemia, cholesterol 
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concentrations could be kept low throughout life,19 and 
tobacco use could be eliminated. We therefore quantiﬁ ed 
risk reduction associated with systolic blood pressure of 
120 mmHg or less, cholesterol concentration of 
5·0 mmol/L or less, post-load blood glucose of 
4·6 mmol/L or less,20 and no smoking on socioeconomic 
inequalities in coronary heart disease.
Methods
Study population
We examined 19 019 non-industrial London-based male 
government employees aged 40–69 years between 
Sept 14, 1967, and Jan 15, 1970 (response rate 74%).21 
Socioeconomic position was based on civil-service 
employment grade. To obtain suﬃ  cient numbers for 
each socioeconomic group and to simplify data 
interpretation, we dichotomised employment grade into 
high (administrative, professional, or executive) and low 
(clerical, messenger, and other unskilled manual 
grades). 886 men from the diplomatic service and the 
British Council could not be given a comparable 
employment grade; therefore, these individuals were 
excluded from all analyses. 
Procedures
A trained observer took a single blood-pressure reading 
from the participant’s left arm with a London School of 
Hygiene sphygmomanometer.22 We recorded systolic 
blood pressure at the ﬁ rst appearance of the Korotkoﬀ  
sounds. We took a capillary blood sample from the 
earlobe after an overnight fast. Participants then drank a 
50-g anhydrous dextrose preparation. We measured 
plasma cholesterol concentration with the standard 
Technicon method N24a,21 and we took a second blood 
sample 2 h later. We measured post-load blood glucose 
concentration by the ferricyanide reduction method on 
an autoanalyser (Technicon method N-9a, NY, USA). 
Those with self-reported diabetes did not undertake the 
glucose-tolerance test and those with a post-load blood 
glucose of 11·1 mmol/L or more were categorised as 
non-IDDM patients. Diabetic participants on insulin 
treatment were classiﬁ ed as insulin-dependent dia betes 
mellitus (IDDM) patients. Smoking status was 
self-reported.
For 99% of men, 15-year mortality data were obtained 
from the National Health Service (NHS) Central Register 
with the NHS identiﬁ cation number assigned to each 
citizen in the UK. Because these records do not cover 
deaths of people who emigrated from the UK and died 
abroad, parti cipants ﬂ agged as embarkees were censored 
at the date of embarkation. Death due to coronary heart 
disease was indicated by codes 410–414 (International 
Classi ﬁ cation of Diseases [ICD]-8 and ICD-9) and codes 
I20–I25 (ICD-10).
We excluded from the analysis men who had any 
missing values for the risk factors of interest—systolic 
blood pressure (6), cholesterol (709), smoking status (8), 
blood glucose or diabetes (135). Diﬃ  culties in retrieving 
a suﬃ  cient sample of blood with the capillary method 
from an incision in the earlobe may have contributed to 
the high rate of missing values for cholesterol (3·7%), 
but this issue existed for both socioeconomic 
groups (p=0·38). We also excluded 16 men who had died 
but for whom the cause of death was unknown. Overall, 
17 186 men were included in the analysis.
Statistical analysis
We chose a follow-up of 15 years to keep the possible 
dilution of eﬀ ects associated with extended mortality 
surveillance to a minimum and to cover a period when 
statins had yet to become a commonly prescribed 
treatment for high cholesterol.21,23 In analyses of baseline 
characteristics and mortality, prevalence of risk factors 
and 15-year coronary heart disease mortality rates between 
men in the high and those in the low employment grade 
were adjusted for age (with 5-year age groups) by the direct 
standardisation method, and compared with the 
Mantel–Haenszel test. For continuous measures, we used 
High employment grade 
(N=12 644)
Low employment grade 
(N=4542)
Diﬀ erence 
(low grade–high grade)
p value
Age (years) 50·9 (0·1) 55·5 (0·1) 4·6 <0·001
Systolic blood pressure (mm Hg) 136·3 (0·2) 137·3 (0·3) 1·0 0·01
Total cholesterol (mmol/L) 5·12 (0·01) 5·02 (0·02) –0·10 <0·001
IDDM 0·3% (32) 0·2% (9) –0·1% 0·55
Non-IDDM 0·7% (82) 1·6% (91) 0·9% <0·001
Post-load blood glucose for non-diabetics (mmol/L) 4·15 (0·01) 4·20 (0·01) 0·05 <0·001
Current smoking 36·7% (4625) 56·0% (2550) 19·3% <0·001
Low-risk group* 1·8% (244) 1·1% (34) –0·7% 0·003
15-year mortality rate† 4·91 (748) 7·06 (514) 2·15 <0·001
Data are mean (SE) or percentage (number). IDDM=insulin-dependent diabetes mellitus. Non-IDDM=non-insulin-dependent diabetes mellitus. *Blood pressure of 
120 mmHg or less; cholesterol concentration of 5·0 mmol/L or less; post-load blood glucose of 4·6 mmol/L or less; and never smoked. †Age-standardised coronary heart 
disease mortality rate per 1000 person-years (number of deaths).
Table 1: Age-adjusted risk factors and coronary heart disease mortality by employment grade 
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linear regression to calculate age-adjusted least square 
means, and tested diﬀ erences between grades with the 
dichotomous grade term.
We estimated the relation between risk factors and 
coronary heart disease mortality with the parametric 
Weibull distribution to model the survival function. With 
this model, hazard ratios (HRs) associated with each risk 
factor and their 95% CIs were calculated for 10 mm Hg 
increase for systolic blood pressure, for 2 mmol/L 
increase for total cholesterol, and for current smokers 
versus ex-smokers or non-smokers. Due to the threshold 
eﬀ ect of glucose on coronary heart disease mortality 
observed previously in this study,20 we calculated the HR 
for 1 mmol/L increase for post-load blood glucose 
concentrations above 4·6 mmol/L, and the HR for indi-
viduals with IDDM and non-IDDM compared with those 
with blood glucose concentrations below 4·6 mmol/L. 
We adjusted for age by both a linear and quadratic term, 
and included a dichotomous term for employment grade. 
All the HRs and CIs were almost identical to those 
computed with a Cox proportional hazards model. With 
the Weibull model, the risk of death from coronary heart 
disease over any period can be calculated as follows:
where χ is the vector of risk factors, β is the vector of 
coeﬃ  cients, and σ is a scale parameter, which is also 
estimated. This model has previously been used in the 
Framingham study to describe risk proﬁ les and the 
eﬀ ects of risk factors on coronary outcomes through the 
Framingham risk score.24
For each person in the analysis, we used the above 
equation to calculate the risk of coronary heart disease on 
the basis of his observed risk factors, with age 
between 40 and 55 years. These risks were summed up 
for all individuals and tabulated by employment grade to 
give the baseline expected number of deaths before any 
intervention. To estimate the eﬀ ect on risk of each 
risk-factor intervention, we applied the intervention to 
each individual and recomputed the risk of coronary heart 
disease with the risk equation. To estimate the eﬀ ect of a 
50% reduction in non-IDDM prevalence, we randomly 
gave 50% of non-IDDM men the non-diabetic status 
when calculating the risk of coronary heart disease. We 
repeated this random allocation ﬁ ve times and averaged 
the expected risk. Sensitivity analyses constraining the 
age to either 50 or 60 years changed the risk of coronary 
heart disease, but had little eﬀ ect on the percentage 
changes in excess risk or the risk ratio between low and 
high employment grade. Separate equations to measure 
the eﬀ ects of best-practice interventions for each speciﬁ c 
risk factor on coronary heart disease mortality yielded 
results similar to those based on a model with all risk 
factors included simultaneously. Thus, we only reported 
the latter analysis. 
Primordial prevention aims to change the conditions 
that determine risk-factor development, thus successful 
prevention will eliminate the risk factors themselves. We 
modelled the eﬀ ect of such prevention by applying the 
best-practice intervention to all individuals, irrespective 
of their risk levels, and additionally setting a low risk 
proﬁ le (ie, systolic blood pressure ≤120 mm Hg, total 
cholesterol ≤5·0 mmol/L, post-load blood glucose 
≤4·6 mmol/L, no non-IDDM, and never smoked) for 
those who had residual non-optimal risk levels or were 
ex-smokers after the best-practice interventions (IDDM 
remained unchanged). In all other respects, the modelling 
corresponds to that described for the best-practice 
interventions.
Role of the funding source
The study sponsors did not contribute to the study design 
and had no role in data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
p(t)=1–exp
χ
σ
log(t)– β–exp( (
HR* (95% CI) for 15-year 
CHD mortality
Best-practice intervention Primordial prevention
Eﬀ ect Reduction in risk 
of CHD mortality
Post-prevention Reduction in risk of 
CHD mortality
Systolic blood pressure 1·18 (1·15–1·20) ↓ 10 mm Hg 14% ≤120 mm Hg 32%
Total cholesterol 1·51 (1·39–1·65) ↓ 2 mmol/L 33% ≤5 mmol/L 33%
IDDM vs glucose reference† 1·79 (0·74–4·32) No change in IDDM 0% No change in IDDM 0%
Non-IDDM vs glucose reference† 2·55 (1·84–3·54) ↓ 50% prevalence No non-IDDM
Post-load blood glucose, per unit 
increase above 4·6 mmol/L
1·14 (1·03–1·25) ↓ 1 mmol/L post-load 
glucose for non-diabetics
2%‡ ≤4·6 mmol/L 3%‡
Current smoking 1·78 (1·59–2·00) Smoking cessation 23% Never smoked 37%
All risk factors .. All above 57% All above 73%
CHD=coronary heart disease. HR=hazard ratio. IDDM=insulin-dependent diabetes mellitus. Non-IDDM=non-insulin-dependent diabetes mellitus. ↓= reduction. *Hazard ratios 
are mutually adjusted, and also adjusted for age and employment grade. †Reference group includes those with blood glucose concentration of 4·6 mmol/L or less. ‡Combined 
eﬀ ect of interventions targeting non-IDDM and high post-load blood glucose.
Table 2: Best-practice interventions and primordial prevention eﬀ ects on coronary heart disease mortality
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Results
Men with low employment grades generally had a less 
favourable risk proﬁ le than those with high grades 
(table 1). Systolic blood pressure, glucose, and proportions 
of current smokers and non-IDDM patients were higher 
in the low employment grade group than in the high 
grade group. However, total cholesterol concentrations 
were slightly greater in the high grade group than in the 
low grade group.
During the 15-year follow-up, 1262 men died from 
coronary heart disease. As expected, low employment 
grade and all risk factors were associated with high 
mortality (table 2). The inclusion of best-practice 
interventions in the model resulted in an overall decrease 
of more than 50% in the risk of coronary heart disease 
mortality at age 55 years (table 2). 
Furthermore, the primordial prevention model sug gests 
that removing all risk factors from the study population 
reduces mortality by nearly three-quarters (table 2).
Table 3 shows 15-year risk of death at age 55 years 
for 100 men in the low employment grades and for 
100 men in the high grades, and the risk diﬀ erence 
between groups. All best-practice interventions lowered 
the 15-year risk of mortality in both groups (table 3). In 
relative terms, the ratio of 15-year coronary heart disease 
mortality risk between the high and low employment 
grade groups is 1·46, and the corresponding post-
intervention risk ratio is 1·32 (table 3). The overall 
reduction in the risk ratio was almost entirely attributable 
to the eﬀ ect of smoking cessation (table 3). Because 
employment grade diﬀ erences in the prevalence of the 
other coronary risk factors were small, best-practice 
interventions that reduced these risk factors had little 
eﬀ ect on the relative risk associated with low socio-
economic position.
Interventions that reduced all the outstanding high 
levels of risk and transformed them into low levels, and 
completely eliminated non-IDDM and smoking (ie, all 
men regarded as non-smokers) further reduced the 
population systolic blood pressure to 115·0 mm Hg, 
cholesterol to 3·1 mmol/L, post-load glucose in 
non-diabetics to 4·0 mmol/L, and did not expose to 
cigarette smoking. The 15-year coronary heart disease 
mortality risk under these circumstances is 2·2 for 
100 men of the high grade employment group and 2·7 
for 100 men of the low grade group (table 3). For the 
relative risk, smoking and blood pressure were the most 
important contributing factors.
Discussion
Our aim was to assess the extent to which the successful 
implementation of best-practice interventions to modify 
coronary heart disease risk factors could reduce 
socioeconomic inequalities in mortality at a population 
15-year risk* of CHD mortality Excess risk Reduction in 
excess risk
Relative risk 
ratio
Change in 
relative risk 
ratio
High 
employment 
grade
Low 
employment 
grade
Best-practice intervention
None 7·5 11·0 3·5 Reference 1·458 Reference
Systolic blood pressure (↓ 10 mm Hg) 6·4 9·4 3·0 13% 1·465 2%
Total cholesterol (↓ 2 mmol/L) 5·1 7·5 2·4 31% 1·473 3%
IDDM prevalence (no change) 7·5 11·0 3·5 0% 1·458 0%
Non IDDM prevalence (↓ 50%) 
Non-diabetics (↓ 1 mmol/L glucose†)
7·4 10·7 3·3 6% 1·441 –4%
Smoking cessation 6·0 7·9 2·0 43% 1·331 –28%
All above 3·3 4·4 1·1 69% 1·323 –30%
Primordial prevention
None 7·8 11·5 3·8 Reference 1·486 Reference
Systolic blood pressure to ≤120 mm Hg 5·4 7·5 2·2 43% 1·402 –17%
Total cholesterol to ≤5·0 mmol/L 5·2 7·8 2·6 31% 1·504 4%
Non IDDM (no change) 7·8 11·5 3·8 0% 1·486 0%
No non-IDDM and post-load glucose to 
≤4·6 mmol/L glucose†
7·6 11·0 3·4 9% 1·453 –7%
Never smoked 5·1 6·9 1·8 52% 1·356 –27%
All above 2·2 2·7 0·5 86% 1·231 –53%
CHD=coronary heart disease. IDDM=insulin-dependent diabetes mellitus. Non-IDDM=non-insulin-dependent diabetes mellitus. ↓=reduction. *15-year risk of CHD 
mortality per 100 men, adjusted to age 55 years. †Combined eﬀ ect of interventions targeting non-IDDM and high post-load blood glucose.
Table 3: Best-practice interventions and primordial prevention eﬀ ects on excess risk and relative risk of coronary heart disease mortality for low versus 
high employment grades 
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level. According to estimates from the population of the 
Whitehall study,21 best-practice interventions to reduce 
classic coronary risk factors, if successfully implemented 
in both high and low socioeconomic groups, could 
eliminate 69% of the diﬀ erence in risk between these 
groups. Reduction of cholesterol con centration and 
smoking cessation account for the largest part of the 
change. Primordial prevention would confer only modest 
additional beneﬁ ts. In relative terms, best-practice 
interventions and primordial pre vention were not very 
successful in reducing relative inequalities in coronary 
heart disease between socio economic groups.
Numerous population-based cohort studies have 
assessed the contribution of the classic risk factors to 
relative socioeconomic inequalities, ignoring the 
contribution to absolute diﬀ erences in coronary heart 
disease between socioeconomic groups. Our quanti-
ﬁ cation suggests that interventions that caused the 
greatest reduction in coronary heart disease in randomised 
controlled trials (best-practice interventions) decrease the 
relative diﬀ erence in coronary heart disease between high 
and low socioeconomic groups only by 30%. Previous 
studies with adjustment-based approaches suggested a 
similar reduction of 15% to 40% in relative risk.5,7 The 
adjustment-based method diﬀ ers from ours in that it 
approximates what would happen after standardisation to 
the risk-factor distribution in the total study population, 
irrespective of whether this is possible.
Smoking cessation made the greatest contribution to 
both relative and absolute risk diﬀ erence in coronary 
heart disease between high and low socioeconomic 
groups. Reductions in the other risk factors had only a 
modest eﬀ ect on relative inequalities. Although smoking 
cessation for all smokers is the ultimate aim of all health 
policies, this may seem a very optimistic goal at a 
population level. Re-calculation of the overall best-practice 
intervention eﬀ ect with smoking prevalence only halved 
suggests a 55% (rather than 69%) drop in mortality 
diﬀ erences between high and low employment grades 
and a 12% (rather than 30%) reduction in the relative 
risk. In this scenario, total cholesterol reduction becomes 
the most important factor to lower absolute socioeconomic 
disparities in coronary heart disease mortality.
The relative approach to socioeconomic inequalities is 
only sensitive to reductions in risk factors that are socially 
patterned. Because cholesterol concentrations were not 
higher in low than in high socioeconomic groups, 
cholesterol reduction did not decrease relative socio-
economic inequalities in coronary heart disease mortality, 
despite substantially lowering mortality diﬀ erence 
between socioeconomic groups. This result shows that 
the determinants of relative socioeconomic inequalities 
may diﬀ er from those of absolute diﬀ erences.5
The proportion of people who had low risk-factor levels 
was small (<2% in our cohort). In other studies, with less 
stringent criteria, this proportion was 15% in a Finnish 
sample5 and 5% in a multiracial study of men in the US 
Atherosclerosis Risk in Communities study.9 In a study in 
Norway—one of the healthiest nations in the world—about 
86% of men at age 40 years had some high risk-factor 
levels and none had low levels in all risk factors, according 
to the 2003 European guidelines criteria.25
Although no evidence-based strategies or ways to 
eliminate completely the classic coronary risk factors 
from the population currently exist, this may not be the 
case in the future. In addition to best-practice prevention, 
interventions that target upstream risk factors—such as 
psychosocial and material circumstances in which people 
live and work—could be eﬀ ective in reducing relative 
inequalities.26–28 Lifetime risk-factor prevention is regarded 
as key to lowering coronary heart disease mortality and 
reducing absolute diﬀ erences between socioeconomic 
groups.29 These two prevention strategies are not mutually 
exclusive. For example, attempts to reduce smoking 
through ﬁ scal policy will both prevent initiation of 
smoking (and ultimately might eliminate smoking) and 
reduce absolute diﬀ erences in smoking between diﬀ erent 
social groups (even if relative diﬀ erences increase). 
We suggest that any prevention programme that 
completely eliminates the four classic coronary risk 
factors from the population would reduce coronary heart 
disease mortality by 73% and absolute socioeconomic 
disparities by 86%. True primordial prevention strategies 
may have greater eﬀ ect than we have suggested here, 
because for several factors we only categorised risk 
according to measures taken in adult life. We do not have 
estimates of risk associated with lifetime low 
concentrations of circulating cholesterol, which will be 
lower than those associated with low concentrations in 
only one period of life. Studies30,31 that have assessed 
genetic variants associated with diﬀ erent lifetime 
concentrations of cholesterol have shown that reductions 
in coronary heart disease risk in randomised controlled 
trials of short (<10 years) duration and in observational 
studies initiated when study participants were middle-
aged underestimated the absolute diﬀ erences in 
coronary-heart disease rates associated with long-term 
diﬀ erences in cholesterol concentrations. Similar results 
apply to other classic risk factors. 
In isolated, non-developed populations with a 
non-sedentary lifestyle and a low-fat diet free of added 
salt and reﬁ ned carbohydrate—such as the Yanomamo 
Indians—average systolic blood pressure is about 
100 mm Hg, total cholesterol 3·1 mmol/L, and 
cardiovascular death is rare.19,32 Thus, we may be 
underestimating the potential of true primordial 
prevention in our analyses. A caveat that would aﬀ ect 
estimates in the opposite direction, but probably to a 
lesser extent, is that a small proportion of individuals 
with high genetically-related increases in cholesterol, 
glucose, or blood pressure33–36 would have levels above 
those used as our cut-oﬀ  points.
The validity of our estimates depends on some 
assumptions and the data used. Instead of risk-factor 
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categories, we used continuous measures of blood 
pressure, cholesterol, and blood glucose, which may 
have improved precision. Our analyses of possible 
risk-factor reductions were based on the eﬀ ects of 
best-practice interventions derived from randomised 
controlled trials or, where possible, meta-analyses of 
such trials—ie, the strongest possible evidence.11–13 This 
approach may provide a more realistic estimation for 
policy than that based on risk-factor standardisation or 
comparisons of exposed and unexposed groups. 
Diﬀ erential treatment between socioeconomic groups 
is an unlikely source of bias in this study because 
treatment for blood pressure was rare (1·7% in both 
high and low grade groups) and eﬀ ective 
cholesterol-lowering interventions had yet to become 
available.21 Prevalence of risk factors and associated 
excess risks of coronary heart disease from the same 
population (rather than from diﬀ erent populations) is 
also a strength of the study.
However, our study is not without limitations. First, the 
ﬁ ndings are based on data from an occupational cohort 
of men and results may not be valid for women or 
non-working people. Nonetheless, diﬀ erences between 
the participants and British men aged 45–64 in 2003 were 
small for total cholesterol (5·1 mmol/L vs 5·5 mmol/L) 
and systolic blood pressure (137 mm Hg vs 135 mm Hg),15 
and there is little evidence of diﬀ erences in the eﬀ ects on 
cardiovascular disease of the studied risk factors between 
men and women, except for greater diabetes-related risk 
of fatal coronary heart disease in women than in men.37,38 
Prevalence of smoking was high in this study population 
compared with that of present populations, and is likely 
to overemphasise the role of smoking in the creation of 
absolute socioeconomic inequalities.
Second, we estimated the beneﬁ ts from interventions 
for each risk factor separately while controlling for others. 
However, we did not take into account the potential 
interaction eﬀ ects between diﬀ erent risk reductions 
because comparable clinical evidence relates to 
single-factor rather than multiple-factor interventions. 
Our predictive models could not capture lag eﬀ ects or 
time trends in risk factors and coronary heart disease 
mortality.39 Furthermore, we estimated the beneﬁ ts of 
best-practice risk factor reductions in terms of lower 
coronary heart disease mortality from observational data 
that are open to confounding. 
Despite these potential limitations, our estimates of 
intervention eﬀ ects did not substantially deviate from 
those reported for coronary heart disease morbidity and 
mortality in clinical trials—eg, 33% reduction in coronary 
heart disease from lowering cholesterol in this study 
versus 20% to 36% reductions observed in lipid lowering 
trials,40 and 15% reduction for lowering systolic blood 
pressure in our analysis versus 10% to 20% reductions in 
relative risk of cardiovascular events in blood-pressure 
lowering trials.41 Although observational data suggest that 
these reductions depend on age, trials provided little 
evidence of any age-speciﬁ c eﬀ ects, supporting our 
analysis in which we combined all age groups.40,41 With 
lifetime reductions in these risk factors, greater eﬀ ects 
than those predicted in our observational data or seen in 
short-term randomised controlled trials would be 
expected.
Finally, we assumed that best-practice interventions are 
implemented equitably and have similar eﬀ ectiveness in 
both high and low socioeconomic groups. This goal is a 
major challenge for policy because there are many issues 
to realise the full potential of interventions in all groups, 
which include unhealthy environments that are not 
conducive to healthy living, together with restricted 
ﬁ nancial and health-care resources. These constraints 
disproportionately aﬀ ect low socioeconomic groups.3
This study provides an example of a novel way of 
quantifying socioeconomic inequalities in health. Al-
though the aim of health practitioners and governments 
is to reduce the classic coronary risk factors and eliminate 
cigarette smoking, population-wide comprehensive 
screening and best-practice interventions still need to be 
implemented. We estimated from a working population 
that such interventions, if implemented equally success-
fully in high and low socioeconomic groups, would 
eliminate most of the socioeconomic inequalities of 
coronary heart disease.
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